Elucidation of anti-SARS-CoV-2 and anti-inflammatory bioactives in Qingyan Dropping Pills via integrated in silico screening and bioactivity validation

Liting Liu, Xinru Li, Xinyue Wang, Peng Zhang, Qi Yang, Tong Geng, Yuefei Wang, Junhua Zhang, Changjian Wang, Jing Yang, Min ZhangFrontiers in Medicine 2025 · DOI

TL;DR

This study investigates Qingyan Dropping Pills (QDP), a traditional Chinese medicine used for COVID-19, by integrating computational and experimental methods. It identifies key bioactive compounds within QDP that exhibit potent anti-SARS-CoV-2 and anti-inflammatory activities, offering a scientific basis for its clinical use and potential for developing new antiviral therapies.

What Problem Does This Paper Address?

The COVID-19 pandemic, caused by SARS-CoV-2, continues to be a global health challenge, exacerbated by viral mutations and the emergence of new variants. While conventional treatments and vaccines exist, there's an ongoing need for effective and accessible therapeutic options. Traditional Chinese Medicine (TCM) has shown promise in managing COVID-19 symptoms and improving recovery, with Qingyan Dropping Pills (QDP) being officially recommended in China. However, the specific bioactive compounds within QDP responsible for its therapeutic effects against SARS-CoV-2 and inflammation remained largely unidentified. This paper aims to bridge this knowledge gap by elucidating these bioactive compounds and their mechanisms of action.

Methods

The researchers employed a multi-faceted approach combining computational (in silico) and experimental (in vitro) techniques:

  • Chemical Profiling: Ultra-Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UPLC-Q/TOF-MS) was used to identify and characterize the chemical compounds present in QDP.
  • Network Pharmacology: This approach was used to predict potential targets of QDP compounds related to COVID-19 and inflammation by analyzing interactions between herbs, compounds, and disease targets. This helped identify promising bioactive candidates.
  • Molecular Docking: To assess the binding affinity of identified compounds to key SARS-CoV-2 proteins (Spike protein (Spro), Main Protease (Mpro), and Papain-Like Protease (PLpro)), molecular docking simulations were performed. This technique predicts how well a small molecule (ligand) fits into the active site of a protein.
  • Surface Plasmon Resonance (SPR) Assay: This method was used to experimentally validate the binding affinity of selected compounds to the target proteins, providing quantitative data on their interaction strength.
  • Fluorescence Resonance Energy Transfer (FRET) Assay: FRET was employed to screen for enzymatic inhibitors of Mpro and PLpro, measuring the direct inhibitory activity of compounds on these viral proteases.
  • Antiviral Activity Assay: The efficacy of compounds in inhibiting SARS-CoV-2 replication was tested in Vero E6 cells infected with the Omicron BA.5 variant.
  • Anti-inflammatory Activity Assay: The ability of compounds to reduce inflammation was evaluated by measuring key inflammatory markers (nitric oxide (NO), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α)) in LPS-induced RAW 264.7 cells.

Datasets

  • QDP Extract: The Qingyan Dropping Pills (QDP) themselves served as the source of compounds.
  • Reference Compounds: 24 standard compounds were used for unambiguous characterization of QDP components.
  • Protein Data Bank (PDB): Structures of SARS-CoV-2 Spro, Mpro, and PLpro were obtained from the PDB for molecular docking.
  • PubChem Database: Compound structures were sourced from PubChem for molecular docking.
  • TCMSP and Swiss Target Prediction Databases: These databases were used for network pharmacology analysis to identify potential targets associated with QDP compounds and COVID-19.

Key Insights and Ideas

  • Multi-Target Approach of TCM: The study reinforces the concept that TCM formulations like QDP work through multiple compounds targeting multiple pathways, offering a holistic approach to complex diseases like COVID-19.
  • Identification of Key Bioactives: The research successfully pinpointed specific compounds within QDP, such as Corilagin (COR), Rhoifolin (RHO), and Hamamelitannin (HAM), as having significant potential against SARS-CoV-2.
  • Dual Antiviral and Anti-inflammatory Action: Several compounds demonstrated not only the ability to inhibit viral targets but also to reduce inflammatory responses, suggesting a dual therapeutic strategy for managing COVID-19.
  • Validation of In Silico Predictions: The study effectively integrated in silico screening with experimental validation, demonstrating the power of computational methods in accelerating drug discovery and confirming predicted interactions.
  • Focus on Key Viral Proteins: The research strategically targeted Spro, Mpro, and PLpro, which are critical for SARS-CoV-2 entry and replication, providing a strong rationale for the identified bioactives.

Key Results

  • 48 Compounds Identified: UPLC-Q/TOF-MS analysis identified 48 compounds in QDP, with 24 unambiguously characterized.
  • 33 Potential Antiviral Candidates: Network pharmacology analysis identified 33 compounds with potential antiviral activity against COVID-19.
  • Strong Binding to Viral Targets: Corilagin (COR), Rhoifolin (RHO), and Hamamelitannin (HAM) showed promising binding affinities to SARS-CoV-2 Spro, Mpro, and PLpro through molecular docking.
  • Experimental Validation of Binding: SPR assays confirmed binding affinity, with COR and RHO showing equilibrium dissociation constants (KD) in the range of 4.515 × 10⁻⁸ M to 7.718 x 10⁻⁶ M. HAM demonstrated strong binding to Spro (KD = 9.33 × 10⁻⁸ M).
  • Enzymatic Inhibition: In FRET assays, COR and RHO inhibited Mpro with IC50 values of 0.73 µM and 21.61 μM, respectively.
  • Antiviral Efficacy: COR showed potent antiviral activity against the SARS-CoV-2 Omicron BA.5 variant in Vero E6 cells, with an EC50 of 12.83 μM.
  • Anti-inflammatory Effects: Compounds like COR, HAM, RHO, Isoliquiritin (ISO), Glycocholic acid (GLYCH), and Gallic acid (GAL) significantly inhibited inflammatory markers (NO, IL-6, IL-1β, TNF-α).

Limitations and Future Work

  • In Vitro to In Vivo Translation: While the study demonstrates promising in vitro results, further in vivo studies are needed to confirm the efficacy and safety of these compounds in animal models and eventually in human clinical trials.
  • Mechanism Elucidation: Although key targets and pathways were identified, a deeper understanding of the precise molecular mechanisms of action for each compound is warranted.
  • Broader Viral Life Cycle: The authors plan to investigate QDP's effects on other stages of the viral life cycle, including replication, assembly, and release.
  • Complex Models: Future work will involve using more complex models, such as organoids, to systematically evaluate the antiviral and immune regulatory effects of QDP in a simulated human respiratory microenvironment.
  • Clinical Trials: Comprehensive clinical trials are necessary to fully ascertain the efficacy and safety of QDP for treating COVID-19 patients.

Summary updated

Abstract

Our study focused on Chinese patent medicine QDP to highlight the anti-SARS-CoV-2 and anti-inflammatory bioactives, providing evidence and insights into its clinical practice in the treatment of COVID-19.
BibTeX
@inproceedings{liu2025elucidation,
  author = {Liting Liu and Xinru Li and Xinyue Wang and Peng Zhang and Qi Yang and Tong Geng and Yuefei Wang and Junhua Zhang and Changjian Wang and Jing Yang and Min Zhang},
  title = {{Elucidation of anti-SARS-CoV-2 and anti-inflammatory bioactives in Qingyan Dropping Pills via integrated in silico screening and bioactivity validation}},
  booktitle = {Frontiers in Medicine},
  year = {2025},
  doi = {10.3389/fmed.2025.1684713},
}
Figure